Health Care Select Sector SPDR

Eli Lilly to participate in the BioCentury-BayHelix East-West BioPharma Summit in Seoul, Korea

Eli Lilly to Participate in BIOCHINA Event in Suzhou, China

Eli Lilly to Participate in BIO-Europe Spring in Lisbon, Portugal

FDA decision on Lilly's oral weight-loss drug Orforglipron expected by April 10, 2026

Eli Lilly and Company will participate in the BIO-Korea 2026 conference in Seoul, Korea.

Modern Wealth Management Increases Holdings in Merck

Blair William & Co. IL Reduces Stake in UnitedHealth Group

Grantham Mayo Van Otterloo & Co. LLC Increased Holdings in Thermo Fisher Scientific in Q3

UnitedHealth Group will pay a quarterly dividend of $2.21 per share

New Study Suggests GLP-1 Drugs May Increase Risk of Bone Injuries

MILESTONE ASSET MANAGEMENT Increases Stake in Eli Lilly and Co.

Optum to Host Virtual Career Event for Southern Region Roles on March 10

Eli Lilly's competitor Novo Nordisk will reportedly partner with Hims & Hers to sell weight-loss drugs, potentially intensifying market competition

Pinnacle Associates Ltd. Increases Stake in Eli Lilly and Company

UnitedHealth Group's Optum to participate in the American College of Cardiology National Conference Career Fair

Eli Lilly and Company to Pay Quarterly Dividend

Eli Lilly's obesity drugs are expected to be available at a discount to U.S. Medicare beneficiaries

Forbes reports Eli Lilly used AI to increase production of its popular GLP-1 drugs.

Analyst discusses Eli Lilly's dominance in the GLP-1 drug market and its outlook for the next decade.

Wall Street Zen Upgrades Eli Lilly and Company to 'Strong-Buy'

Peraso

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

Decent

Edesa Biotech

Cre8 Enterprise - CL

AN2 Therapeutics

Day One Biopharmaceuticals

Epsium Enterprise

Silynxcom

Aptera Motors - B

STOK

ARKG

SBIO

IBBQ

Biogen and Stoke Therapeutics reported positive clinical results for zorevunersen in Dravet syndrome, indicating potential as a disease-modifying therapy. Biogen also shared new data on SPINRAZA for spinal muscular atrophy (SMA) and advanced salanersen into Phase 3 trials. These developments enhance Biogen's position in neurology and rare diseases, with a focus on high unmet needs. Investors should monitor upcoming regulatory milestones and the company's ability to convert late-stage assets into successful products amidst competition. Analysts highlight both risks and potential rewards related to Biogen's evolving pipeline.

Simplywall

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Stoke Therapeutics

iShares Biotechnology ETF

Biogen

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Biogen’s Dravet And SMA Advances Add Depth To Long Term Story

C4 Therapeutics (NASDAQ: CCCC) presented at the TD Cowen Healthcare Conference, outlining plans for its lead myeloma drug, cemsidomide, aiming for accelerated approval. CEO Andrew Hirsch emphasized the company's focus on targeted protein degradation and a sustainable pipeline. C4's Phase I study showed a 36% overall response rate, with higher rates at increased doses. The company has initiated the MOMENTUM Phase II study and plans a combination study with elranatamab. They target a 12-month enrollment period and aim for a first NDA submission for cemsidomide by 2028.

Market Beat

C4 Therapeutics

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

The U.S. FDA has approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, Pylarify, which targets prostate-specific membrane antigen (PSMA). This new formulation aims to enhance production capacity by increasing batch size by approximately 50% and improving profit margins. Following the announcement, Lantheus shares rose about 3% in extended trading.

Reuters

iShares Global Healthcare

Lantheus

US FDA approves Lantheus' new prostate cancer imaging formulation

HIMZ

March 6 (Reuters) -* NOVO AND HIMS END FEUD, WILL SELL OBESITY DRUGS TOGETHER- BLOOMBERG NEWS* NOVO AND HIMS PLAN TO ANNOUNCE A NEW PARTNERSHIP AS SOON AS MONDAY - BLOOMBERG NEWS Source text: Further company coverage:

SPDR S&P Health

Defiance Daily Target 2X Long HIMS ETF

Defiance Daily Target 2X Long NVO ETF

Defiance Leveraged Long +Income HIMS ETF

Hims & Hers Health

Novo And Hims End Feud, Will Sell Obesity Drugs Together- Bloomberg News

ExThera Medical and its former executive, Sanja Ilic, face U.S. charges for concealing patient deaths related to a blood filtration device. The company will pay a $750,000 fine and $5.69 million in forfeiture. Ilic has agreed to plead guilty, facing a recommended 34-month prison sentence. Prosecutors allege that Ilic failed to report adverse events to the FDA, misleading the agency about the device's safety. The case highlights serious complications experienced by cancer patients who traveled to Antigua for treatment, with some patients dying after the procedure.

Mara

Blood filter start-up, ex-executive face US charges for concealing deaths

Immuneering reported a smaller-than-expected Q4 loss, with a net loss per share of -$0.18, beating analyst estimates of -$0.31. R&D expenses decreased to $9.3 million from $14.9 million year-over-year. The company ended 2025 with $217 million in cash, ensuring funding until 2029. Analysts maintain a "buy" rating, with a median 12-month price target of $14.00, representing a potential upside of 181.1% from its recent closing price of $4.98.

Immuneering

Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs

Johnson & Johnson (J&J) has received FDA approval for the combination of Tecvayli and Darzalex Faspro for adults with relapsed or refractory multiple myeloma. This new treatment aims to set a standard of care for patients who have undergone at least one prior therapy. The approval is based on the Phase III MajesTEC-3 study, which demonstrated significant improvements in progression-free and overall survival rates. Adverse events were similar to existing treatments, with manageable side effects. J&J emphasizes this approval as a milestone in enhancing patient outcomes in multiple myeloma treatment.

Pharmaceutical Technology

SPDR S&P Health Equip

iShares US Medical Devices

Johnson & Johnson

J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma

Lantheus Holdings, Inc. announced FDA approval for PYLARIFY TruVu™ (piflufolastat F 18) injection, a new formulation of its PSMA PET imaging agent for prostate cancer. Set to launch in Q4 2026, this formulation aims to enhance diagnostic performance and patient access. The approval follows data from pivotal studies OSPREY and CONDOR, ensuring similar safety and effectiveness as the original PYLARIFY. The new formulation is designed for larger batch production, improving supply chain efficiency and patient availability, addressing the growing demand for prostate cancer diagnostics.

StockTitan

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection | LNTH Stock News

How BBP-418’s Positive Phase 3 FORTIFY Readout At BridgeBio Pharma (BBIO) Has Changed Its Investment Story

Bridgebio Pharma

Direxion S&P Biotech Bear 3X

How BBP-418’s Positive Phase 3 FORTIFY Readout At BridgeBio Pharma (BBIO) Has Changed Its Investment Story

The FDA has granted several approvals in late February and early March across various therapeutic areas. Notable approvals include Boehringer Ingelheim's Hernexeos for advanced non-small cell lung cancer, Ascendis Pharma's Yuviwel for children with achondroplasia, BioMarin's expanded indication for Palynziq in pediatric phenylketonuria patients, and Novo Nordisk's Sogroya for growth disorders. Additionally, Johnson & Johnson's Tecvayli plus Darzalex Faspro was approved for relapsed multiple myeloma. These approvals mark significant advancements in treatment options for patients with specific medical conditions.

rttnews

Novo Nordisk AS

Ascendis Pharmac

BioMarin Pharma

FDA Roundup: First-Line Hernexeos, Weekly Yuviwel, Expanded Palynziq & Sogroya Indications

Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting

Tip Ranks

Argenx

Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting

March 6 (Reuters) - CSPC Pharmaceutical Group Ltd:* HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN U.S. Further company coverage:

Scpharmaceuticals

CSPC Pharmaceutical Says PDE4B Inhibitor Obtains U.S. Clinical Trial Approval

HALO

Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment

marketscreener

Halozyme Therap

Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment

March 6 (Reuters) - WHO Foundation:* WHO FOUNDATION ANNOUNCES COLLABORATION WITH LILLY TO STRENGTHEN HEALTH SYSTEMS FOR OBESITY CARE* WHO FOUNDATION: LILLY IS COMMITTING $1.68 MILLION TO WHO FOUNDATION UNTIL 2029 IN SUPPORT OF EFFORTS TO STRENGTHEN HEALTH SYSTEMS FOR OBESITY CARE Source text: Further company coverage:

Eli Lilly

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

WHO Foundation Announces Collaboration With Lilly To Strengthen Health Systems For Obesity Care

TNYA

Alnylam Pharmaceuticals has signed a $1.23 billion collaboration deal with Tenaya Therapeutics to discover novel genetic targets for heart disease. Alnylam will pay $10 million upfront and up to $1.13 billion in milestone payments for successful drug development. The partnership aims to identify and validate up to 15 genetic targets over two years, with Alnylam responsible for the commercialization of any resulting therapies. This move is part of Alnylam's strategy to expand its presence in the cardiovascular market, following the success of its ATTR-CM therapy, Amvuttra.

Tenaya Therapeutics

Alnylam Pharma

Direxion Daily Biotech Top 5 Bull 2X ETF

Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal

6 of the 11 S&amp;P sectors are green right now in this moment of time. $Select Sect Spdr Util(XLU.US) $SPDR FD Consumer Staples(XLP.US) $Health Care Select Sector SPDR(XLV.US) $Real Est Select Spdr(XLRE.US) $Comm Servcies Select Sector SPDR(XLC.US) $Spdr Material(XLB.US). $SPDR Energy Select(XLE.US) flat the others redSource: Sunrise Trader

Real Est Select Spdr

Comm Servcies Select Sector SPDR

Spdr Material

SPDR Energy Select

Select Sect Spdr Util

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

Top 3 sectors intraday and right now = $Spdr Select Tech(XLK.US) $Health Care Select Sector SPDR(XLV.US) $Spdr Material(XLB.US)Source: Sunrise Trader

Spdr Select Tech

three green sectors $SPDR FD Consumer Staples(XLP.US) $Health Care Select Sector SPDR(XLV.US) $Real Est Select Spdr(XLRE.US)Source: Sunrise Trader

SPDR FD Consumer Staples

S&amp;P 500 cap weighted sectors that are green right now in this order $Select Sect Spdr Util(XLU.US) $Comm Servcies Select Sector SPDR(XLC.US) $Health Care Select Sector SPDR(XLV.US) $Spdr Select Indu(XLI.US) $SPDR FD Consumer Staples(XLP.US) $Real Est Select Spdr(XLRE.US) rest are redSource: Sunrise Trader

S&P 500

SPDR S&P 500

VG S&P 500 Grw

Spdr Select Indu